Literature DB >> 2467331

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.

R G Robinson1, G M Blake, D F Preston, A J McEwan, J A Spicer, N L Martin, A V Wegst, D M Ackery.   

Abstract

Two hundred and two patients with bone pain from metastatic cancer were treated with 40 microCi/kg of Sr-89. Patients were followed with pain diaries, records of medication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup survived at least 3 months, including 100 with prostate and 28 with breast carcinoma. Eighty of the 100 patients with prostate cancer responded, and 25 of the 28 breast cancer patients improved. Ten patients with prostate cancer and five with breast cancer became pain free. Little hematologic depression was noted. Sr-89 kinetic studies showed that strontium taken up in osteoblastic areas remained for 100 days. The tumor-to-marrow absorbed dose ratio was 10:1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467331     DOI: 10.1148/radiographics.9.2.2467331

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  21 in total

1.  Advances in diagnosis and management of prostate cancer.

Authors:  S L Goldenberg
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

Review 2.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Authors:  Shi-Ming Tu; Sue-Hwa Lin; Donald A Podoloff; Christopher J Logothetis
Journal:  Clin Adv Hematol Oncol       Date:  2010-05

Review 4.  Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.

Authors:  Jatinder Goyal; Emmanuel S Antonarakis
Journal:  Cancer Lett       Date:  2012-04-17       Impact factor: 8.679

5.  Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.

Authors:  Wei Bo Li; Vera Höllriegl; Paul Roth; Uwe Oeh
Journal:  Radiat Environ Biophys       Date:  2008-01-19       Impact factor: 1.925

Review 6.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  The management of painful bone metastases with an emphasis on radionuclide therapy.

Authors:  Darren J Hillegonds; Stephen Franklin; David K Shelton; Srinivasan Vijayakumar; Vani Vijayakumar
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

Review 8.  Managing bone metastases and reducing skeletal related events in prostate cancer.

Authors:  Benjamin A Gartrell; Fred Saad
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

9.  EANM procedure guideline for treatment of refractory metastatic bone pain.

Authors:  Lisa Bodei; Marnix Lam; Carlo Chiesa; Glenn Flux; Boudewijn Brans; Arturo Chiti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

Review 10.  Prostate cancer, Incidence, management and outcomes.

Authors:  E J Small
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.